John Bonfiglio Ph.D

John Bonfiglio Ph.D General Information

Biography

On March 15, 2023, we appointed Dr. John Bonfiglio as the Interim President of JanOne Biotech. Dr. John Bonfiglio, age 68, has over 30 years' experience in the biotech/pharmaceutical industry, including over 20 years as a C-level executive in the biotechnology industry. He has served as a member of the boards of directors of the Sequella Corporation, a US-based biotechnology company, and Avipero Therapeutics, a breast cancer pharmaceutical research company, since November 2019. From January 2007 to February 2010, Dr. Bonfiglio was the President and Chief Executive Officer of Argos Therapeutics, a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases. From May 2011 to November 2014, he served as the President and Chief Executive Officer of Oragenics Corporation, a development-stage company focused on developing vaccines and novel antibiotics to fight infectious diseases, including coronaviruses and multidrug-resistant organisms. From February 2015 to April 2017, Dr. Bonfiglio was a member of the board of directors of TapImmune, Inc., also serving as its President and Chief Operating Officer from July 2016 to April 2017; in 2018, TapImmune, Inc. merged with Marker Therapeutics, Inc. (Nasdaq: MRKR). From June 2019 to November 2019, he was the Chief Operating Officer of QRONS Corporation, a biotechnology company dedicated to developing, biotech products, treatments, and technologies that create a platform to combat neuronal diseases. Dr. Bonfiglio received his BS in chemistry from State University of New York (SUNY) at Stony Brook; his MS in synthetic organic chemistry from the University of California at San Diego (UCSD); and his Ph.D. in synthetic organic chemistry from UCSD. In addition, he received his MBA from Pepperdine University.